Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...
Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...
The deadline to apply for the program is 4:30 p.m. on Feb. 20. The class is limited to 30 Moorhead residents, ages 18 and ...
We are thrilled to announce MoCA Arlington’s summer camp season! Do you have a young artist at home? From painting and ...
The district will be transitioning the program from an opt-out model — in which students are automatically part of the dual ...
The Department of Social Welfare and Development Field Office 7, in partnership with the Philippine Statistics Authority, continues the registration of Pantawid Pamilyang Pilipino ...